Paragon Associates & Paragon Associates Ii Joint Venture Dia Medica Therapeutics Inc. Put Options Transaction History
Paragon Associates & Paragon Associates Ii Joint Venture
- $56.1 Million
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding DMAC
# of Institutions
33Shares Held
3.85MCall Options Held
5.9KPut Options Held
1.4K-
Vanguard Group Inc Valley Forge, PA1.01MShares$3.07 Million0.0% of portfolio
-
First Manhattan CO New York, NY850KShares$2.58 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA239KShares$724,8820.0% of portfolio
-
Bleichroeder LP New York, NY222KShares$673,6200.19% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA209KShares$634,2750.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $80.1M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...